The health giant has increased its dividend for 54 consecutive years, putting it among the elite of Dividend Aristocrats . Also, until the quick rise and fall of hepatitis C drug Olysio, Johnson & Johnson had a better than three-decade-long streak of increasing its adjusted earnings per share on a year-over-year basis.